United States

Esperion Therapeutics Inc (ESPR.OQ)

ESPR.OQ on NASDAQ Stock Exchange Global Market

9 Dec 2016
Change (% chg)

$0.29 (+2.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ESPR.OQ


Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies... (more)


Beta: 2.13
Market Cap(Mil.): $275.61
Shares Outstanding(Mil.): 22.55
Dividend: --
Yield (%): --


  ESPR.OQ Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -2.62 -- --
ROI: -21.31 -0.36 15.24
ROE: -21.48 -0.94 16.58

BRIEF-Esperion Therapeutics reports qtrly loss per share $0.77

* Esperion Therapeutics Inc says expects full-year net cash used in operating activities in 2016 will be approximately $65 million

Nov 03 2016

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

Oct 13 2016

BRIEF-BB Biotech reports 5.1 pct passive stake in Esperion Therapeutics

* BB Biotech AG reports 5.1 pct passive stake in Esperion Therapeutics as of September 22, 2016 - SEC filing Source text for Eikon: Further company coverage:

Sep 27 2016

BRIEF-Esperion Therapeutics reports Q2 net loss of $14 mln

* Estimates current cash resources are sufficient to fund operations into 2019

Aug 04 2016

BRIEF-Esperion Therapeutics provides regulatory update for Bempedoic Acid

* Esperion Therapeutics Inc says intends to initiate planned CVOT in statin intolerant patients who are at high risk for CV disease in Q4 of 2016

Jun 28 2016

Earnings vs. Estimates